Last reviewed 2026-06-01 · How we verify

Xe 133 (xenon (133Xe) gas)

Xe 133 (generic name: xenon (133Xe) gas) is a Inhalation Diagnostic Agent [EPC] drug developed by Mallinckrodt. It is currently FDA-approved for Pulmonary Function Evaluation, Lung Imaging, Cerebral Blood Flow Assessment.

Xenon-133 is a small molecule used as a diagnostic agent. It has been studied in clinical trials for assessing pulmonary function in patients undergoing pulmonary surgical procedures and those with lung diseases.

At a glance

Approved indications

• Pulmonary Function Evaluation
• Lung Imaging
• Cerebral Blood Flow Assessment

Common side effects

• Adverse reactions
• Nausea

Key clinical trials

• Comparison of 133Xe Scintigraphy With 19F MRI for Evaluation of Lung Ventilation Function: A Non-Inferiority Comparison (DIAL1001007) (EARLY/Phase 1)
• Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Resection Surgery (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Xe 133 CI brief — competitive landscape report
• Xe 133 updates RSS · CI watch RSS
• Mallinckrodt portfolio CI

Frequently asked questions about Xe 133

Related

• Drug class: All Inhalation Diagnostic Agent [EPC] drugs
• Manufacturer: Mallinckrodt — full pipeline
• Therapeutic area: All drugs in Respiratory
• Indication: Drugs for Pulmonary Function Evaluation
• Indication: Drugs for Lung Imaging
• Indication: Drugs for Cerebral Blood Flow Assessment

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing